Controversial value of prophylactic cranial irradiation (PCI) in NSCLC in terms of survival
benefit prompted us to explore the possible risk factors for brain metastasis (BM) during the
course of EGFR-TKIs therapy from EGFR-mutated advanced lung adenocarcinoma and
identify the potential population most likely to benefit from PCI, because BM remains a
therapeutically challenging issue. We retrospectively reviewed the records of 134 patients
with EGFR-mutated advanced lung adenocarcinoma between 2008 and 2012. The …

Background Brain metastasis (BM) remains a therapeutically challenging issue, which often
predicts poor prognosis. Moreover, there are still some patients developing BM during the
course of EGFR-TKIs therapy, although EGFR-TKIs are effective for EGFR-mutated NSCLC
patients with BM. Therefore, controversial value of prophylactic cranial irradiation (PCI) in
NSCLC in terms of survival benefit prompted us to explore the possible risk factors for BM
during the course of EGFR-TKIs therapy from EGFR-mutated advanced lung …